NICE nod for J&J's Invokana combinations
This article was originally published in Scrip
Executive Summary
Johnson & Johnson is on a roll with its combination diabetes products using Invokana (canagliflozin), having received positive draft guidance from NICE for a number of combinations immediately following a recommendation for the metformin combination from the European Medicines Agency's CHMP on 21 February.